Aethlon Medical, Inc. (OQ:AEMD)
Business Focus: Advanced Medical Equipment & Technology
Feb 21, 2024 07:01 am ET
Aethlon Medical Enters Into Materials Transfer Agreement for Santersus AG's NucleoCapture and HemoNucleoCapture Devices
Aethlon Medical Will Perform Pre-Clinical Studies to Explore Potential Synergies With its First-in-Class Hemopurifier® Blood Filtration System
Feb 14, 2024 03:15 pm ET
Aethlon Medical Announces Fiscal Third Quarter Financial Results and Provides Corporate Update
Conference Call to be Held Today at 4:30 p.m. ET
Feb 07, 2024 07:00 am ET
Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 14, 2024
SAN DIEGO, Feb. 7, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal third quarter ended December 31, 2023, at 4:15 p.m. ET on Wednesday, February 14, 2024.
Nov 14, 2023 03:15 pm ET
Aethlon Medical Announces Fiscal Second Quarter Financial Results and Provides Corporate Update
Conference Call to be Held Today at 4:30 p.m. ET
Nov 13, 2023 07:01 am ET
Aethlon Medical Announces Appointment of James B. Frakes, M.B.A. as Interim Chief Executive Officer and Guy Cipriani, M.B.A. as Chief Operating Officer
SAN DIEGO, Nov. 13, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that James B. Frakes, M.B.A., Chief Financial Officer of the Company, was appointed as Interim Chief Executive Officer, replacing Charles J. Fisher, Jr. M.D. Mr. Frakes also was appointed as a member of the Board of Directors and will remain as Chief Financial Officer of the Company. Additionally, Guy Cipriani, formerly Chief Business Officer, has been appointed as the Company's Ch
Nov 06, 2023 07:01 am ET
Aethlon Medical to Release Second Quarter Financial Results and Host Conference Call on November 14, 2023
SAN DIEGO, Nov. 6, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening viral infections and for use in organ transplantation, today announced that it will issue financial results for its second quarter ended September 30, 2023, at 4:15 p.m. ET on Tuesday, November 14, 2023.
Oct 10, 2023 08:01 am ET
Aethlon Receives Clearance From Drug Controller General of India For Potential Phase 1 Trial of its Hemopurifier® in Oncology
SAN DIEGO, Oct. 10, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening viral infections and for use in organ transplantation, today announced that it has received clearance from the Drug Controller General of India (DCGI), the central drug authority in India, to conduct a phase 1 safety, feasibility and dose-finding trial of the company's Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® or Opdivo®
Oct 04, 2023 08:01 am ET
Aethlon Announces Reverse Stock Split
SAN DIEGO, Oct. 4, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that its Board of Directors has approved a 1-for-10 reverse stock split of the Company's common stock, effective at 5:00 p.m. ET on October 4, 2023. The Company's shares of common stock will begin trading on a reverse split-adjusted basis commencing upon market opening on October 5, 2023.
Jul 24, 2023 08:01 am ET
Aethlon Medical Signs Collaboration Agreement with 34 Lives to Evaluate the Ability of the Hemopurifier® to Expand the Utility of Unused, Donated Kidneys for Transplant
Proof-of-Concept Studies to Support the Use of the Hemopurifier in the Ex Vivo Organ Perfusion Circuit
Jul 06, 2023 02:17 pm ET
Aethlon Medical Appoints Medical Device and Biomedical Executive, Nicolas Gikakis, to its Board of Directors
SAN DIEGO, July 6, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced the appointment of Nicolas Gikakis to its Board of Directors (Board), effective July 3, 2023. Mr. Gikakis will also serve as a member of the Nominating and Corporate Governance Committee of the Board. In connection with the appointment of Mr. Gikakis as a director, the authorized size of Aethlon Medical's Board was increased to six members.
Jun 28, 2023 04:15 pm ET
Aethlon Medical Announces Fiscal Year End Financial Results and Provides Corporate Update
Conference Call to be Held Today at 4:30pm ET
Jun 22, 2023 08:01 am ET
Aethlon Medical to Release Fourth Quarter and Year End Financial Results and Host Conference Call on June 28, 2023
SAN DIEGO, June 22, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it will issue financial results for its fourth quarter ended March 31, 2023, at 4:15 p.m. EST on Wednesday, June 28, 2023.
Jun 21, 2023 08:01 am ET
Aethlon Medical Announces Investigation of the Hemopurifier® for Use in Organ Transplantation
Research to Confirm the Hemopurifier's Ability to Remove Harmful Viruses and Exosomes From Harvested Organs
Jun 01, 2023 03:51 pm ET
Aethlon Medical to Present at the 13th Annual LD Micro Invitational
SAN DIEGO, June 1, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life-threatening infectious diseases, today announced that Guy Cipriani, Senior Vice President and Chief Business Officer, and James Frakes, Chief Financial Officer, will present a company overview at the 13th Annual LD Micro Invitational on Wednesday, June 7, 2023, at 1:30 PM PT.
May 22, 2023 08:01 am ET
Aethlon Medical Receives Ethics Board Approval to Add Second Site to its Ongoing Clinical Trial of its Hemopurifier® to Treat Severe COVID-19 in India
SAN DIEGO, May 22, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today announced that it has received Ethics Review Board (ERB) approval from the Maulana Azad Medical College (MAMC), for a second site for its ongoing clinical trial of Aethlon's Hemopurifier® to treat severe COVID-19 in India.
Feb 13, 2023 03:15 pm ET
Aethlon Medical Announces Third Quarter Financial Results and Provides Corporate Update
SAN DIEGO, Feb. 13, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today reported financial results for its third quarter ended December 31, 2022 and provided an update on recent developments.
Feb 06, 2023 07:01 am ET
/C O R R E C T I O N -- Aethlon Medical, Inc./
In the news release, Aethlon Medical to Release Third Quarter Financial Results and Host Conference Call on February 13, 2023, issued 06-Feb-2023 by Aethlon Medical, Inc. over PR Newswire, we are advised by the company that in the 1st and 2nd paragraphs, both mentions of "February 6, 2023" should read "February 13, 2023" as originally issued inadvertently. The complete, corrected release follows:
Feb 06, 2023 07:01 am ET
Aethlon Medical to Release Third Quarter Financial Results and Host Conference Call on February 13, 2023
SAN DIEGO, Feb. 6, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ: AEMD), a company developing medical therapeutics to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its third quarter ended December 31, 2022, at 4:15 p.m. EST on Monday, February 6, 2023.
Jan 31, 2023 07:01 am ET
Aethlon Medical to Present at Sequire Biotechnology Conference on February 2nd, 2023
Presentation on Thursday, February 2nd, 2023 at 10:00 AM ET
Jan 30, 2023 09:49 am ET
Thinking about buying stock in Exela Technologies, Genius Group, Aethlon Medical, G Medical Innovations, or Heart Test Laboratories?
NEW YORK, Jan. 30, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for XELA, GNS, AEMD, GMVD, and HSCS.
Jan 30, 2023 07:01 am ET
Aethlon Medical Announces Contract with NAMSA to Advance Hemopurifier Clinical Programs in Cancer
SAN DIEGO, Jan. 30, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious diseases, today announced that it has entered into an agreement with NAMSA, a world leading MedTech Contract Research Organization (CRO) offering global end-to-end development services to oversee the company's clinical trials investigating the Hemopurifier, Aethlon's immunotherapeutic device , for oncology indications.
Nov 14, 2022 03:15 pm ET
Aethlon Medical Announces Second Quarter Financial Results and Provides Corporate Update
SAN DIEGO, Nov. 14, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today reported financial results for its second quarter ended September 30, 2022 and provided an update on recent developments.
Nov 02, 2022 02:43 pm ET
Aethlon Medical to Release Second Quarter Financial Results and Host Conference Call on November 14, 2022
SAN DIEGO, Nov. 2, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical therapeutics to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its second quarter ended September 30, 2022, at 4:15 p.m. EST on Monday, November 14, 2022.
Sep 12, 2022 08:35 am ET
Life Sciences Virtual Investor Conference Agenda Announced for September 15th
Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Virtual Investor Conference to be held on September 15th. Individual investors, institutional investors,...
Sep 06, 2022 08:01 am ET
Aethlon Medical to Present at Two Investor Conferences in September
SAN DIEGO, Sept. 6, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life-threatening infectious diseases, today announced that it will be presenting at two investor conferences in September. These include the H.C. Wainwright 24th Annual Global Investment Conference, being held virtually and in New York from Sept. 12-14, 2022, and the Life Sciences Investor Forum, being held virtually on Sept. 15, 2022. At both conferences, Steven LaRosa, M.D., Chief Medical Officer and Chief Scientific Of
Aug 10, 2022 08:30 am ET
Thinking about buying stock in Aethlon Medical, Bark, Jumia Technologies, Array Technologies, or Exicure?
NEW YORK, Aug. 10, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AEMD, BARK, JMIA, ARRY, and XCUR.
Aug 09, 2022 04:15 pm ET
Aethlon Medical Announces First Quarter Financial Results and Provides Corporate Update
SAN DIEGO, Aug. 9, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today reported financial results for its first quarter ended June 30, 2022 and provided an update on recent developments.
Aug 03, 2022 12:47 pm ET
Aethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 9, 2022
SAN DIEGO, Aug. 3, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical therapeutics to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its first quarter ended June 30, 2022, at 4:15 p.m. EST on Tuesday, August 9, 2022.
Aug 03, 2022 09:41 am ET
Thinking about buying stock in AMTD IDEA Group, Aethlon Medical, Poseida Therapeutics, Kymera Therapeutics, or SoFi Technologies?
NEW YORK, Aug. 3, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMTD, AEMD, PSTX, KYMR, and SOFI.
Aug 01, 2022 08:30 am ET
Thinking about buying stock in Geovax Labs, Aethlon Medical, Tonix Pharmaceuticals, Inflarx NV, or Redbox Entertainment?
NEW YORK, Aug. 1, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GOVX, AEMD, TNXP, IFRX, and RDBX.
Jul 28, 2022 02:01 pm ET
Aethlon Medical Announces Publication of Peer-Reviewed Journal Article Describing Hemopurifier Resin Binding of Seven COVID-19 Variants
SAN DIEGO, July 28, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today announced the publication of a peer-reviewed journal article in PLOS ONE. The article, titled "Removal of Clinically Relevant SARS-CoV-2 Variants by An Affinity Resin Containing Galanthus nivalis Agglutinin," contains data demonstrating that the proprietary GNA affinity resin of the Aethlon Hemopurifier® efficiently captures seven clinically relevant variants of the SARS-CoV-2 v
Jul 25, 2022 09:31 am ET
Thinking about buying stock in Aethlon Medical, Tonix Pharmaceuticals, REE Automotive, Kaival Brands, or vTv Therapeutics?
NEW YORK, July 25, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AEMD, TNXP, REE, KAVL, and VTVT.
Jul 11, 2022 08:01 am ET
Aethlon Medical Announces U.S. FDA Approval of Hemopurifier COVID-19 Study Protocol Amendment
Approval eliminates the requirement for previous dialysis treatment, potentially enabling accelerated enrollment in the ongoing clinical study
Jun 28, 2022 04:15 pm ET
Aethlon Medical Announces Fiscal Year End Financial Results and Provides Corporate Update
SAN DIEGO, June 28, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening infectious diseases, today reported financial results for its fiscal year ended March 31, 2022 and provided an update on recent developments.
Jun 21, 2022 08:01 am ET
Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 28, 2022
SAN DIEGO, June 21, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its fiscal year ended March 31, 2022, at 4:15 p.m. EST on Tuesday, June 28, 2022.
May 24, 2022 04:21 pm ET
/C O R R E C T I O N -- Aethlon Medical, Inc./
In the news release, Aethlon Medical to Present at the H.C. Wainwright Global Investment Conference, issued 17-May-2022 by Aethlon Medical, Inc. over PR Newswire, we are advised by the company that in the "Company Webcasting Link" section, the link should only be directing to https://journey.ct.events/view/a3033427-1449-4cbb-a684-ba4c0c800bc6 instead of https://protect-us.mimecast.com/s/FlEjCADgrLhVV4BsQLlBH?domain=nam10.safelinks.protection.outlook.com as originally issued inadvertently. The complete, corrected release follows:
May 17, 2022 08:01 am ET
Aethlon Medical to Present at the H.C. Wainwright Global Investment Conference
SAN DIEGO, May 17, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced that it will be presenting at the H.C. Wainwright Global Investment Conference. The conference will be held at the Fontainebleau Miami Beach Hotel in Miami Beach, Fla. and virtually from May 23-26, 2022.
May 02, 2022 08:01 am ET
Aethlon Medical Publishes In Vitro Studies Demonstrating Hemopurifier Resin Binding of Seven Clinically Relevant COVID-19 Variants
Viral capture efficiency ranged from 53% to 89% for the seven COVID-19 variants testedSAN DIEGO, May 2, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced the publication of a pre-print manuscript featuring data that demonstrated Aethlon's proprietary GNA affinity resin was able to bind seven clinically relevant SARS-CoV-2 variants in vitro, including the Delta and Omicron variants. Viral capture efficiency with the GNA affinity resin ranged from 53%
Mar 28, 2022 08:01 am ET
Aethlon Medical, Inc. Appoints Angela Rossetti to Board of Directors
SAN DIEGO, March 28, 2022 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon") (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced the appointment of Angela Rossetti to the Aethlon Board of Directors, effective April 1, 2022. Ms. Rossetti replaces Sabrina Martucci Johnson, who has served on the Aethlon Board of Directors since 2018 and is stepping down on April 1, 2022 to focus on her other roles.
Feb 14, 2022 03:15 pm ET
Aethlon Medical Announces Third Quarter Financial Results and Provides Corporate Update
SAN DIEGO, Feb. 14, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious diseases, today reported financial results for its third quarter ended December 31, 2021 and provided an update on recent developments.
Jan 31, 2022 07:01 am ET
Aethlon Medical to Release Third Quarter Financial Results and Host Conference Call on February 14, 2022
SAN DIEGO, Jan. 31, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its third quarter fiscal year 2022, ended December 31, 2021, at 4:15 p.m. EST on Monday, February 14, 2022.
Nov 09, 2021 03:15 pm ET
Aethlon Medical Announces Second Quarter Financial Results and Provides Corporate Update
SAN DIEGO, Nov. 9, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious diseases, today reported financial results for its second quarter ended September 30, 2021 and provided an update on recent developments.
Nov 02, 2021 08:02 am ET
Aethlon Medical to Release Second Quarter Financial Results and Host Conference Call on November 9, 2021
SAN DIEGO, Nov. 2, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its second quarter fiscal year 2022, ended September 30, 2021, at 4:15 p.m. EST on Tuesday, November 9, 2021.
Oct 12, 2021 08:01 am ET
Aethlon Medical Announces Peer-Reviewed Publication of Two Case Studies of Critically Ill COVID-19 Patients Treated with the Hemopurifier®
SAN DIEGO, Oct. 12, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced the publication of a manuscript in the peer-reviewed journal Frontiers in Medicine describing two cases of critically ill COVID-19 patients treated with the Hemopurifier®, Aethlon's therapeutic blood filtration system. The publication, titled "Removal of COVID-19 spike protein, whole virus, exosomes and exosomal microRNAs by the Hemopurifier® lectin-affinity cartridge in critically Ill patients with COV
Oct 05, 2021 09:31 am ET
Thinking about buying stock in Flux Power, Amplify Energy, Salem Media, Aethlon Medical, or Progenity?
NEW YORK, Oct. 5, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FLUX, AMPY, SALM, AEMD, and PROG.
Sep 30, 2021 08:02 am ET
Aethlon Medical Announces Contracting with PPD to Advance Hemopurifier Clinical Programs
SAN DIEGO, Sept. 30, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced that it has entered into an agreement with PPD, Inc. (Nasdaq: PPD), a leading global contract research organization (CRO), for PPD to oversee the company's clinical studies investigating the Hemopurifier, Aethlon's therapeutic blood filtration system, for infectious disease indications.
Sep 22, 2021 08:30 am ET
Thinking about buying stock in Aethlon Medical, Innate Pharma, Predictive Oncology, Bridgeline Digital, or Aterian?
NEW YORK, Sept. 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AEMD, IPHA, POAI, BLIN, and ATER.
Sep 07, 2021 08:01 am ET
Aethlon Medical to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
SAN DIEGO, Sept. 7, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced that it will be presenting at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference. The conference is being held virtually from September 13-15, 2021.
Aug 17, 2021 08:30 am ET
Thinking about buying stock in Powerbridge Technologies, Danimer Scientific, Dolphin Entertainment, Rekor Systems, or Aethlon Medical?
NEW YORK, Aug. 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PBTS, DNMR, DLPN, REKR, and AEMD.
Aug 13, 2021 08:30 am ET
Thinking about buying stock in Boxlight, Pilgrim's Pride, Co-Diagnostics, Sesen Bio, or Aethlon Medical?
NEW YORK, Aug. 13, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BOXL, PPC, CODX, SESN, and AEMD.
Aug 09, 2021 04:15 pm ET
Aethlon Medical Announces First Quarter Financial Results and Provides Corporate Update
SAN DIEGO, Aug. 9, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, today reported financial results for its first quarter ended June 30, 2021 and provided an update on recent developments.
Jul 29, 2021 01:32 pm ET
Aethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 9, 2021
SAN DIEGO, July 29, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial results for its first quarter fiscal year 2022, ended June 30, 2020, at 4:15 p.m. EST on Monday, August 9, 2021.
Jul 12, 2021 08:30 am ET
Thinking about buying stock in Tempest Therapeutics, Cemtrex, Exela Technologies, Aethlon Medical, or Bridgeline Digital?
NEW YORK, July 12, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TPST, CETX, XELA, AEMD, and BLIN.
Jun 24, 2021 04:15 pm ET
Aethlon Medical Announces Fiscal Year End Financial Results and Provides Corporate Update
SAN DIEGO, June 24, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, today reported financial results for its fiscal year ended March 31, 2021 and provided an update on recent developments.
Jun 21, 2021 03:27 pm ET
Aethlon Medical to Release Fourth Quarter Financial Results and Host Conference Call on June 24, 2021
SAN DIEGO, June 21, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial results for its fourth quarter fiscal year 2021, ended March 31, 2021, at 4:15 p.m. ET on Thursday, June 24, 2021.
Jun 10, 2021 10:55 am ET
Thinking about buying stock in Trxade Health, Clean Energy Fuels, Athene, TAL Education Group, or Aethlon Medical?
NEW YORK, June 10, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MEDS, CLNE, ATH, TAL, and AEMD.
Jun 10, 2021 09:10 am ET
Aethlon Medical Announces $12.425 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
SAN DIEGO, June 10, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq:AEMD), a medical device technology company focused on unmet needs in global health, today announced that it has entered into a definitive agreement with a single institutional investor for the purchase in a registered direct offering of 1,380,555 shares of its common stock, at a purchase price per share of $9.00, priced at-the-market under Nasdaq rules.
Jun 09, 2021 08:30 am ET
Thinking about buying stock in Aethlon Medical, Checkpoint Therapeutics, ContextLogic, Clean Energy Fuels, or Solid Biosciences?
NEW YORK, June 9, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AEMD, CKPT, WISH, CLNE, and SLDB.
Feb 10, 2021 03:15 pm ET
Aethlon Medical Announces Third Quarter Financial Results and Provides Corporate Update
SAN DIEGO, Feb. 10, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device therapeutic company focused on developing products to diagnose and treat life and organ threatening diseases, today reported financial results for its third quarter ended December 31, 2020 and provided an update on recent developments.
Feb 04, 2021 07:02 am ET
Aethlon Medical to Release Third Quarter Financial Results and Host Conference Call on February 10, 2021
SAN DIEGO, Feb. 4, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial results for its third quarter fiscal year 2021, ended December 31, 2020, at 4:15 p.m. EST on Wednesday, February 10, 2021.
Jan 06, 2021 07:02 am ET
Aethlon Medical Expands Leadership Team with Appointment of Chief Business Officer and Chief Medical Officer
SAN DIEGO, Jan. 6, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, today announced the expansion of its executive team with two key appointments: Guy Cipriani as Senior Vice President and Chief Business Officer, and Steven LaRosa, M.D., as Chief Medical Officer. In his new role, Mr. Cipriani will oversee business development and partnerships, while also contributing to fundraising and corporate development. Dr. LaRosa will be responsible for the clinical develop
Jan 04, 2021 07:02 am ET
Aethlon Medical to Present at the H.C. Wainwright BioConnect 2021 Conference
SAN DIEGO, Jan. 4, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, today announced that the company will participate in the virtual H.C. Wainwright BioConnect 2021 Conference to be held Jan. 11-14, 2021.
Dec 16, 2020 07:02 am ET
Aethlon Medical Announces First Patient Treated in First-in-Human Clinical Trial of HEMOPURIFIER® in Head and Neck Cancer
SAN DIEGO, Dec. 16, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, announced today that the first patient has been treated in the Company's first-in-human Early Feasibility Study (EFS) evaluating the HEMOPURIFIER® in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. The study is enrolling patients at UPMC Hillman Cancer Center in Pittsburgh, PA. (Hemopurifier Plus Pembrolizumab in Head and Neck Cancer - Full Text View - Cli
Nov 03, 2020 07:01 am ET
Aethlon Announces Appointment of Charles J. Fisher, Jr., M.D. as Chief Executive Officer
SAN DIEGO, Nov. 3, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, announced today the appointment of Charles J. Fisher, Jr., M.D., as Chief Executive Officer, effective as of October 30, 2020. Dr. Fisher joined Aethlon as a member of Aethlon's Board of Directors and has served as Chairman of the Board since November 2017. Mr. Ed Broenniman replaced Dr. Fisher as the Chairman of the Board effective as of October 30, 2020. Dr. Fisher brings an impressive record
Oct 28, 2020 04:15 pm ET
Aethlon Medical Announces Second Quarter Financial Results and Provides Corporate Update
SAN DIEGO, Oct. 28, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, today reported financial results for its second quarter ended September 30, 2020 and provided an update on recent developments.
Oct 19, 2020 08:01 am ET
Aethlon Medical To Release Second Quarter Financial Results and Host Conference Call on October 28, 2020
SAN DIEGO, Oct. 19, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial results for its second quarter fiscal year 2021, ended September 30, 2020, at 4:15 pm Eastern time on Wednesday, October 28, 2020.
Aug 06, 2020 08:00 am ET
Aethlon Medical Announces Collaboration with University of Pittsburgh on NIH Grant for Head and Neck Cancer
SAN DIEGO, Aug. 6, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in oncology and viral diseases announced today that the National Institute for Dental and Craniofacial Research (NIDCR), a unit of the National Institutes for Health (NIH), has awarded a grant for studies in head and neck cancer that will be a collaborative project between Aethlon and the UPMC Hillman Cancer Center at the University of Pittsburgh.
Aug 04, 2020 12:18 pm ET
Aethlon Medical To Release First Quarter Financial Results and Host Conference Call on August 11, 2020
SAN DIEGO, Aug. 4, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial results for its first quarter fiscal year 2021, ended June 30, 2020, at 4:15 pm Eastern time on Tuesday, August 11, 2020.
Jun 25, 2020 04:15 pm ET
Aethlon Medical Announces Fiscal Year Financial Results and Provides Corporate Update
SAN DIEGO, June 25, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, today reported financial results for its fiscal year ended March 31, 2020 and provided an update on recent developments.
Jun 22, 2020 08:31 am ET
Aethlon Medical Presents Hemopurifier® Data at the American Association for Cancer Research 2020 Annual Meeting
SAN DIEGO, June 22, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, today released positive ex vivo data demonstrating the ability of a laboratory version of the Company's Hemopurifier® to capture tumor-derived exosomes in several forms of cancer. The data were presented in e-poster format by Dr. Annette Marleau, the Company's Senior Director of Research, at the American Association for Cancer Research (AACR) Virtual Annual Meeting II, on June 22, 2020.
Jun 18, 2020 09:19 am ET
Aethlon Announces FDA Approval of IDE Supplement for COVID-19 Patients
SAN DIEGO, June 18, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, announced today that the U.S. Food and Drug Administration (FDA) has approved a supplement to the Company's existing Investigational Device Exemption (IDE) for the Company's Hemopurifier® in viral disease to allow for the testing of the Hemopurifier in patients with SARS-CoV-2/COVID-19 in a new feasibility study.
Jun 16, 2020 08:30 am ET
Aethlon Medical To Release Fourth Quarter Financial Results and Host Conference Call on June 25, 2020
SAN DIEGO, June 16, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial results for its fourth quarter fiscal year 2020, ended March 31, 2020, at 4:15pm Eastern time on Thursday, June 25, 2020.
Mar 24, 2020 08:58 am ET
Aethlon Announces Issuance of European Patent for the Hemopurifier® in Cancer
SAN DIEGO, March 24, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in global health, announced today that it has received European Patent No. 1,993,600 ("the '600 Patent") entitled "Extracorporeal Removal of Microvesicular Particles." The '600 patent embodies Aethlon's Hemopurifier® technology designed for the depletion of immune suppressive, and potentially cancer-promoting, exosomes from the circulatory system.
Nov 01, 2019 04:15 pm ET
Aethlon Medical Announces Second Quarter Financial Results and Provides Corporate Update
SAN DIEGO, Nov. 1, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, today reported financial results for its second quarter ended September 30, 2019 and provided an update on recent developments.
Oct 29, 2019 03:17 pm ET
Aethlon Medical To Release Second Quarter Financial Results and Host Conference Call on November 1, 2019
SAN DIEGO, Oct. 29, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial results for its second quarter fiscal year 2020, ended September 30, 2019, at 4:15pm Eastern time on Friday, November 1, 2019.
Oct 14, 2019 03:55 pm ET
Aethlon Announces Reverse Stock Split
SAN DIEGO, Oct. 14, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD) ("Aethlon" or the "Company"), a therapeutic medical device and technology company focused on unmet needs in global health, announced today that at the annual meeting of stockholders of the Company, held October 14, 2019, its stockholders voted to approve a proposal authorizing the Board of Directors of the Company to effect a reverse stock split of Aethlon's outstanding common stock. Following the special meeting of stockholders, the Board of Directors approved a 1-for-15 reverse stock split.
Oct 07, 2019 08:31 am ET
Aethlon Medical Announces FDA Approval Of IDE For Oncology Indications
SAN DIEGO, Oct. 7, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in global health, announced today that the FDA has approved its Investigational Device Exemption (IDE) application to initiate an Early Feasibility Study (EFS) of the Company's proprietary Hemopurifier® in patients with head and neck cancer in combination with standard of care pembrolizumab (Keytruda).
Oct 03, 2019 08:31 am ET
Aethlon Medical Receives Extension from Nasdaq to Regain Compliance with Continued Listing Requirements
SAN DIEGO, Oct. 3, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health, announced today that on October 2, 2019, Nasdaq granted Aethlon Medical an extension of time to regain compliance with the exchange's continued listing requirement of a minimum $2.5 million of stockholders' equity.
Sep 24, 2019 10:30 am ET
Aethlon Announces Collaboration to Identify Exosomes Involved in Cancer Progression and Treatment Resistance
SAN DIEGO, Sept. 24, 2019 /PRNewswire/ -- EXOSOME SCIENCES, a subsidiary of Aethlon Medical, Inc. (Nasdaq: AEMD), announced a research collaboration to identify and characterize exosomes derived from patients with solid tumors such as pancreas cancer, as well as from families with genetically high risk of developing cancer. These cancer-derived exosomes may serve as early markers for cancer diagnostics, cancer progression and treatment resistance.
Sep 16, 2019 08:31 am ET
Aethlon Medical Receives National Cancer Institute Contract Award
SAN DIEGO, Sept. 16, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health, announced today that the National Cancer Institute (NCI) has awarded the Company an SBIR Phase 2 contract for Topic 359, a solicitation entitled "Technologies for Differential Isolation of Exosomes and Oncosomes." This solicitation prioritized the advancement of technologies for isolating exosomes from biofluids for applications in oncology research and clinical care. This contract will be funded with Federal funds from the NCI, National In
Aug 14, 2019 04:15 pm ET
Aethlon Medical Announces First Quarter Financial Results and Provides Corporate Update
SAN DIEGO, Aug. 14, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health, today reported financial results for its first quarter ended June 30, 2019 and provided an update on recent developments.
Aug 07, 2019 01:36 pm ET
Aethlon Medical To Release First Quarter Financial Results and Host Conference Call on August 14, 2019
SAN DIEGO, Aug. 7, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health, today announced that it will issue financial results for its first quarter fiscal year 2020, ended June 30, 2019, at 4:15pm Eastern time on Wednesday, August 14, 2019.
Jul 02, 2019 09:31 am ET
Thinking about buying stock in Aethlon Medical, Alibaba, Canopy Growth, Eros International, or Tilray?
NEW YORK, July 2, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AEMD, BABA, CGC, EROS, and TLRY.
Jul 01, 2019 04:15 pm ET
Aethlon Medical Announces Fiscal Year End Financial Results and Provides Corporate Update
SAN DIEGO, July 1, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health, today reported financial results for its fiscal year ended March 31, 2019 and provided an update on recent developments.
Jul 01, 2019 08:31 am ET
Aethlon Medical, Inc. and SeaStar Medical, Inc. Announce Strategic Joint Cross-Licensing Agreement
SAN DIEGO and CARDIFF, Calif., July 1, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD) and SeaStar Medical, Inc. today announced a cross-licensing agreement to jointly develop their respective medical devices to address the care and management of critically ill patients.
May 13, 2019 08:00 am ET
Aethlon Medical Announces Collaboration With Prostate On-Site Project (POP), Host Of The Jerry Colangelo Sports Legend Golf Classic, To Engage With Participants For CTE Studies
PHOENIX, May 13, 2019 /PRNewswire/ -- Aethlon Medical Inc. (Nasdaq: AEMD) and its diagnostic subsidiary, Exosome Sciences, in collaboration with the Translational Genomics Research Institute (TGen) and the Prostate On-Site Project (POP), announced that Aethlon, TGen and POP will engage with participants for their studies of chronic traumatic encephalopathy (CTE) in living individuals during the 18th annual Jerry Colangelo Sports Legends Golf Classic in Phoenix.
Apr 17, 2019 08:27 am ET
Aethlon Medical Releases Shareholder Update
SAN DIEGO, April 17, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today released the following shareholder update authored by its CEO, Timothy C. Rodell, M.D.
Mar 07, 2019 07:47 am ET
Aethlon Medical, Inc. Announces Appointment of Lisa M. Boswell as Director, Quality Systems and Regulatory Affairs
SAN DIEGO, March 7, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device company focused on addressing critical unmet needs in global health, announces the appointment of Lisa M. Boswell, to the position of Director, Quality Systems and Regulatory Affairs. Ms. Boswell has over 15 years of experience in Quality Control, Quality Assurance and Regulatory Affairs in both the biopharmaceutical and medical device industries, most recently as Director, Quality Assurance and Regulatory Affairs at ZOLL Data Systems, Inc.
Feb 11, 2019 03:15 pm ET
Aethlon Medical Announces Third Quarter Financial Results and Provides Corporate Update
SAN DIEGO, Feb. 11, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health, today reported financial results for the third quarter ended December 31, 2018 and provided an update on recent developments.
Feb 04, 2019 01:49 pm ET
Aethlon Medical To Release Quarterly Financial Results and Host Conference Call on February 11, 2019
SAN DIEGO, Feb. 4, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health, today announced that it will issue financial results for the third quarter of fiscal year 2019, ended December 31, 2018, at 4:15 pm eastern time on Monday, February 11, 2019.
Jan 18, 2019 07:35 am ET
Market Trends Toward New Normal in Roper Technologies, The AES, D.R. Horton, Forrester Research, Aethlon Medical, and CyberOptics — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Roper Technologies, Inc. (NYSE:ROP), The AES Corporation (NYSE:AES),...
Dec 13, 2018 07:29 am ET
Aethlon Announces Appointment of Timothy Rodell as Interim Chief Executive Officer
SAN DIEGO, Dec. 13, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health, announced today the appointment of Timothy C. Rodell, M.D., FCCP, as Interim Chief Executive Officer, effective as of December 10, 2018. Dr. Rodell joins Aethlon from GlobeImmune, Inc. where he was President, and Chief Executive Officer and a member of their board of directors prior to the shareholder majority acquisition of the company. Dr. Rodell brings an impressive record of results in global, strategic and operational roles to Aethlon
Nov 27, 2018 06:21 am ET
Aethlon Medical's Cancer Therapy Receives "Breakthrough Device" Designation from the U.S. Food and Drug Administration
SAN DIEGO, Nov. 27, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health, announced today that it has received a "Breakthrough Device" designation from the U.S. Food and Drug Administration (FDA) to support the advancement of the Aethlon Hemopurifier® for the treatment of cancer. The Aethlon Hemopurifier is a first-in-class technology designed for the rapid depletion of cancer-promoting exosomes and life-threatening viruses.
Nov 12, 2018 08:15 am ET
Research Report Identifies Prudential Financial, Second Sight Medical Products, Acushnet, Repligen, Scorpio Tankers, and Aethlon Medical with Renewed Outlook — Fundamental Analysis, Calculating Forwar
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Prudential Financial, Inc. (NYSE:PRU), Second Sight Medical Products,...
Nov 06, 2018 03:15 pm ET
Aethlon Medical Announces Second Quarter Fiscal Year 2019 Results
SAN DIEGO, Nov. 6, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health, today announced results for its fiscal second quarter ended September 30, 2018.
Nov 01, 2018 08:30 am ET
Aethlon Medical To Release Quarterly Financial Results and Host Conference Call on November 6, 2018
SAN DIEGO, Nov. 1, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health today announced it will issue financial results for the second quarter fiscal year 2019 ended September 30, 2018 at 4:15pm eastern time on Tuesday, November 6, 2018.
Oct 29, 2018 11:59 am ET
Aethlon Medical to Present at the NYC Oncology Conference
SAN DIEGO, Oct. 29, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq:AEMD), an immunotherapeutic technology company focused on unmet needs in global health, today announced that its CEO, Jim Joyce, will present at the NYC Oncology Investor Conference on Tuesday, October 30, 2018 at 10:50 a.m. Eastern Time. The event is being held at Rockefeller Center, 1270 6th Avenue, New York, New York.
Oct 18, 2018 09:25 am ET
Investor Expectations to Drive Momentum within Aethlon Medical, Jaguar Animal Health, Advaxis, Forestar Group, Platform Specialty Products, and AVEO Pharmaceuticals — Discovering Underlying Factors of
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Aethlon Medical, Inc. (NASDAQ:AEMD), Jaguar Animal Health, Inc....
Oct 16, 2018 08:15 am ET
Aethlon Medical to Present at the 2018 BIO Investor Forum
SAN DIEGO, Oct. 16, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq:AEMD), an immunotherapeutic technology company focused on unmet needs in global health, today announced that its CEO, Jim Joyce, will present at the 2018 BIO Investor Forum on Thursday, October 18, 2018 at 3:15 p.m. Pacific Time. The event is being held at the Westin St. Francis Hotel in San Francisco, California. A live audio webcast of the presentation can be accessed at http://www.aethlonmedical.com/news-media/presentations. A replay of the webcast will be available until January 15, 2019.
Sep 18, 2018 08:46 am ET
Aethlon Medical Receives National Cancer Institute Award
SAN DIEGO, Sept. 18, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that the National Cancer Institute (NCI) has awarded the Company a government grant (number 1R43CA232977-01). The title of this SBIR Phase I grant is "The Hemopurifier Device for Targeted Removal of Breast Cancer Exosomes from the Blood Circulation."
Aug 27, 2018 08:00 am ET
Research Report Identifies Ball, Aethlon Medical, NeoGenomics, Del Taco Restaurants, Arconic, and Agilysys with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ball Corporation (NYSE:BLL), Aethlon Medical, Inc. (NASDAQ:AEMD),...
Aug 08, 2018 04:15 pm ET
Aethlon Medical Announces First Quarter Fiscal Year 2019 Results
SAN DIEGO, Aug. 8, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced results for its fiscal first quarter ended June 30, 2018.
Aug 02, 2018 08:15 am ET
Aethlon Medical To Release Financial Results for the First Quarter Fiscal Year 2019 and Host Conference Call on August 8, 2018
SAN DIEGO, Aug. 2, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense today announced it will issue financial results for the first quarter fiscal year 2019 ended June 30, 2018 at 4:15pm eastern time on Wednesday, August 8, 2018.
Jul 23, 2018 08:15 am ET
Aethlon Medical Announces Issuance of Hemopurifier® Patent To Treat Life-Threatening Viruses
SAN DIEGO, July 23, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced the issuance of U.S. Patent No. 10,022,483 ("the '483 Patent"). The '483 Patent protects key features of the Aethlon Hemopurifier, a first-in-class therapeutic device, designed to treat viral infections. Previously, Aethlon received U.S. Patent Number 7,226,429, protecting the Company's proprietary methods of treating viral infections. Together, this intellectual property further secures Aethlon's position a
Jun 25, 2018 09:15 am ET
Guy Cipriani Joins Aethlon Medical's Board of Directors
SAN DIEGO, June 25, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced the appointment of Guy Cipriani to its Board of Directors. Mr. Cipriani qualifies as an independent director under the Nasdaq Rules.
Jun 21, 2018 07:55 am ET
New Research: Key Drivers of Growth for Nicolet Bankshares, Vitamin Shoppe, Aethlon Medical, Barrett Business Services, Veracyte, and TPG Specialty Lending — Factors of Influence, Major Initiatives an
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Nicolet Bankshares Inc. (NASDAQ:NCBS), Vitamin Shoppe, Inc (NYSE:VSI),...
Jun 08, 2018 04:15 pm ET
Aethlon Medical Announces Fiscal 2018 Results
SAN DIEGO, June 8, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced results for its fiscal year ended March 31, 2018.
May 31, 2018 08:45 am ET
Aethlon Medical To Release 2018 Fiscal Year End Financial Results and Host Conference Call on June 8, 2018
SAN DIEGO, May 31, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense today announced it will issue financial results for the fiscal year ended March 31, 2018 at 4:15pm Eastern Time on Friday, June 8, 2018.
May 01, 2018 07:55 am ET
Report: Developing Opportunities within AMC Networks, JELD-WEN Holding, Blueprint Medicines, Northwest Bancshares, Anika Therapeutics, and Aethlon Medical — Future Expectations, Projections Moving int
NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AMC Networks Inc. (NASDAQ:AMCX), JELD-WEN Holding,...
Mar 22, 2018 08:00 am ET
Study of Blood Test to Detect and Monitor Chronic Traumatic Encephalopathy (CTE) in Former NFL Players Set for Kick-Off in Phoenix
PHOENIX and SAN DIEGO, March 22, 2018 /PRNewswire/ -- Exosome Sciences, Inc., a diagnostic subsidiary of Aethlon Medical, Inc. (Nasdaq: AEMD), today announced the initiation of an Institutional Review Board (IRB) approved protocol for a research study involving retired NFL players and a data-supported biomarker candidate to potentially detect and monitor Chronic Traumatic Encephalopathy (CTE) in living individuals. The sample collection will be conducted in collaboration with Kendall Van Keuren-Jensen, Ph.D., co-director of the Translational Genomics Research Institute's (TGen) Center for No
Mar 19, 2018 08:25 am ET
Research Report Identifies Chatham Lodging Trust (REIT), Independent Bank Group, NeoGenomics, Black Knight, Aethlon Medical, and PRA Group with Renewed Outlook — Fundamental Analysis, Calculating Forw
NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Chatham Lodging Trust (REIT) (NYSE:CLDT), Independent...
Feb 12, 2018 05:32 am ET
Aethlon Medical To Present at the American Society for Microbiology Biothreats Meeting
SAN DIEGO, Feb. 12, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that its CEO, Jim Joyce will give a presentation at the 2018 American Society for Microbiology (ASM) Biothreats Meeting. The presentation entitled: "A Broad-Spectrum Platform to Address Life-Threating Viral Infections," is scheduled to begin at 8:30am eastern on February 14th. The presentation slide-deck will be made available on the Aethlon Medical website at https://www.aethlonmedical.com/news-media/present
Feb 01, 2018 03:15 pm ET
Aethlon Medical Announces Fiscal 2018 Third Quarter Results
SAN DIEGO, Feb. 1, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced results for its fiscal third quarter ended December 31, 2017.
Jan 29, 2018 07:15 am ET
Aethlon Medical to Release Third Quarter Fiscal Year 2018 Financial Results and Host Conference Call on February 1, 2018
SAN DIEGO, Jan. 29, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense today announced it will issue third quarter results for the fiscal year ended March 31, 2018 at 4:15 pm eastern time on Thursday, February 1, 2018.
Jan 23, 2018 07:15 am ET
Aethlon Medical Announces Validation Completion for European Patent Protecting Methods of Quantifying Exosomes
SAN DIEGO, Jan. 23, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that validation has completed and the opposition period expired for European Patent Number 2591359, entitled "METHODS AND COMPOSITIONS FOR QUANTIFYING EXOSOMES." The patent was validated in Germany, France, Great Britain, and Spain.
Jan 18, 2018 06:49 am ET
Aethlon Medical Announces Allowance of U.S. Patent that Broadens Protection for the Aethlon Hemopurifier® to Treat Viral Infections
SAN DIEGO, Jan. 18, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced that the United States Patent and Trademark Office has allowed U.S. Patent Application Number 14/490,418 ("the '418 Application"), entitled "METHOD FOR REMOVAL OF VIRUSES FROM BLOOD BY LECTIN AFFINITY HEMODIALYSIS." The allowed claims of the '418 Application embody cartridges for the Aethlon Hemopurifier®, which removes viral particles from the blood or plasma of infected patients. The '418 Application is a co
Jan 17, 2018 08:15 am ET
Market Trends Toward New Normal in FTD Companies, Acuity Brands, MINDBODY, Actinium Pharmaceuticals, XG Technology, and Aethlon Medical — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Jan. 17, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of FTD Companies, Inc. (NASDAQ:FTD), Acuity Brands...
Jan 10, 2018 08:01 am ET
Sabrina Martucci Johnson Joins Aethlon Medical's Board of Directors
SAN DIEGO, Jan. 10, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced the appointment of Sabrina Martucci Johnson to its Board of Directors and to its Audit Committee. Ms. Johnson qualifies as an independent director under the Nasdaq Rules.
Nov 29, 2017 06:45 am ET
Aethlon Medical Names Dr. Charles J. Fisher Chairman of the Board
SAN DIEGO, Nov. 29, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced the appointment of Charles ("Chuck") J. Fisher, Jr., MD as Chairman of its Board of Directors.
Nov 09, 2017 12:58 pm ET
Dr. Charles J. Fisher, Jr. Joins Aethlon Medical's Board of Directors
SAN DIEGO, Nov. 9, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced the appointment of Charles ("Chuck") J. Fisher, Jr., MD to its Board of Directors and to its Audit Committee. Dr. Fisher qualifies as an independent director under the Nasdaq Rules, and his appointment fills an open Board seat.
Nov 02, 2017 05:15 pm ET
Aethlon Medical Announces Fiscal 2018 Second Quarter Results
SAN DIEGO, Nov. 2, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced results for its fiscal second quarter ended September 30, 2017.
Oct 30, 2017 08:30 am ET
Aethlon Medical to Release Financial Results for the Second Quarter Fiscal Year 2018 and Host Conference Call on November 2, 2017
SAN DIEGO, Oct. 30, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense today announced it will issue financial results for the second quarter fiscal year 2018 ended September 30, 2017 at 4:15pm eastern time on Thursday, November 2, 2017.
Oct 16, 2017 08:15 am ET
Aethlon Medical Announces Large-Scale Production Collaboration
SAN DIEGO, Oct. 16, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that it has established a collaboration with iBio, Inc. (NYSE AMERICAN: IBIO) to support potential large-scale production of the Aethlon Hemopurifier®. iBio is a leading developer of plant-based biopharmaceuticals.
Oct 11, 2017 09:15 am ET
Aethlon Medical to Present at the 2017 BIO Investor Forum
SAN DIEGO, Oct. 11, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq:AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced that its Chairman and CEO, Jim Joyce, will be a featured presenter at the 2017 BIO Investor Forum in San Francisco, CA on October 18, 2017, at 2:15pm (pacific time) at the Westin St. Francis Hotel. The presentation will be live audio webcast through a link available in the upcoming events section of the company's website at http://www.aethlonmedical.com/news-media/presentations. A replay of the webcast will be
Oct 10, 2017 02:27 pm ET
Aethlon Medical Announces Compliance With Nasdaq Listing Criteria
SAN DIEGO, Oct. 10, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced that Nasdaq has formally notified the Company that it has demonstrated compliance with all applicable requirements for the continued listing of its common stock on The Nasdaq Capital Market, including the $2.5 million stockholders' equity requirement. As previously disclosed, the Nasdaq Hearings Panel required the Company to evidence compliance with the stockholders' equity requirement by October 31, 2017. As a
Oct 02, 2017 07:00 am ET
Aethlon Medical Announces Pricing of $6 Million Public Offering
SAN DIEGO, Oct. 2, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announces the pricing of a public offering of an aggregate of 5,454,546 units. Each unit is comprised of one share of common stock (or common stock equivalent) and one common warrant to purchase one share of common stock. The units are being offered at a price of $1.10 per unit.
Sep 14, 2017 08:30 am ET
Aethlon Medical Receives National Cancer Institute Contract Award
SAN DIEGO, Sept. 14, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that the National Cancer Institute (NCI) has awarded the Company a government contract (number HHSN261201700022C). The title of this SBIR Topic 359 Phase I contract is "Device Strategy for Selective Isolation of Oncosomes and Non-Malignant Exosomes."
Sep 12, 2017 08:30 am ET
Aethlon Medical Receives Expedited Access Pathway Designation from FDA to Accelerate U.S. Access to the Hemopurifier® as a Treatment for Life-Threatening Viruses
SAN DIEGO, Sept. 12, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that it has received an Expedited Access Pathway (EAP) designation from the United States Food and Drug Administration (FDA) to support the advancement of the Aethlon Hemopurifier® to treat life-threatening viruses. The FDA EAP program was established to facilitate more rapid patient access to breakthrough technologies with the potential to address life threatening disease conditions for which no approved or c
Sep 06, 2017 10:12 am ET
Aethlon Medical to Present at the 19th Annual Rodman & Renshaw Global Investment Conference on September 11, 2017
SAN DIEGO, Sept. 6, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense today announced that its Chairman and CEO, Jim Joyce, will be a featured presenter at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City on September 11, 2017, at 3:00pm at the Lotte New York Palace Hotel in New York City. The presentation will be live audio webcast through a link available in the upcoming events section of the company's website at http://www.aethlonmedical.com/news-media/present
Aug 10, 2017 05:15 pm ET
Aethlon Medical Announces Fiscal 2018 First Quarter Results
SAN DIEGO, Aug. 10, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced results for its fiscal first quarter ended June 30, 2017.
Aug 03, 2017 09:00 am ET
Aethlon Medical To Release Financial Results for the First Quarter Fiscal Year 2018 and Host Conference Call on August 10, 2017
SAN DIEGO, Aug. 3, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense today announced it will issue financial results for the first quarter fiscal year 2018 ended June 30, 2017 at 4:15pm eastern time on Thursday, August 10, 2017.
Jul 19, 2017 08:11 am ET
Aethlon Medical Announces the Grant of a U.S. Patent Protecting Methods of Capturing MHC Antigen Associated Exosomes
SAN DIEGO, July 19, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that the United States Patent and Trademark Office has granted U.S. Patent Number 9,707,333 (the '333 Patent), entitled "EXTRACORPOREAL REMOVAL OF MICROVESICULAR PARTICLES."
Jun 28, 2017 05:15 pm ET
Aethlon Medical Announces Fiscal 2017 Results
SAN DIEGO, June 28, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced results for its fiscal year ended March 31, 2017.
Jun 26, 2017 09:15 am ET
Aethlon Medical To Release 2017 Fiscal Year End Financial Results and Host Conference Call on June 28, 2017
SAN DIEGO, June 26, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced it will issue financial results for the fiscal year ended March 31, 2017 at 4:15pm eastern time on Wednesday, June 28, 2017.
Jun 14, 2017 09:00 am ET
Aethlon Medical To Present Clinical Study Results at The BIO International Convention
SAN DIEGO, June 14, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that Company Chairman and CEO, Jim Joyce will present at the 2017 BIO International Convention (BIO 2017) on June 21, 2017 at 11:15 AM Pacific Time. BIO 2107, which is being held at the San Diego Convention Center, attracts more than 16,000 biotechnology industry executives from 76 countries. Mr. Joyce will present virus capture data from a recently concluded FDA-approved feasibility study that was designed to
Jun 06, 2017 09:00 am ET
Aethlon Medical, Inc., Announces Upcoming Presentation and Webcast at the LD Micro Invitational Conference on June 6, 2017
SAN DIEGO, June 06, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense today announced that James Joyce, CEO, will be presenting an overview of the company's clinical strategy to combat infectious viral pathogens, including bioterror and pandemic threats that are not addressed with drug and vaccine therapies at today's LD Micro Invitational at 11:30AM Pacific Time at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Mr. Joyce's presentation will also be live audio webcast through a link availabl
May 24, 2017 09:00 am ET
Aethlon to Present at the LD Micro Invitational Conference on June 6, 2017
SAN DIEGO, May 24, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense today announced James Joyce, CEO, will be a featured presenter at the LD Micro Invitational on Tuesday, June 6, 2017 at 11:30AM Pacific Time at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. The presentation will be live audio webcast through a link available in the upcoming events section of the company's website at http://aethlonmedical.investorroom.com/events-and-presentations-details.
Apr 24, 2017 10:25 am ET
Aethlon Medical Releases Shareholder Update
SAN DIEGO, April 24, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today released the following shareholder update authored by its Chairman and CEO, Jim Joyce.
Apr 04, 2017 10:03 am ET
Aethlon Medical Discloses Tech Nation Interview On National Public Radio
SAN DIEGO, April 4, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, disclosed today that an interview conducted with Company CEO Jim Joyce on the weekly Tech Nation radio program is available to be accessed online at https://www.podomatic.com/podcasts/technation/episodes/2017-03-31T04_14_59-07_00. The 27 minute interview begins at minute six of the program and ends at minute 33.
Mar 13, 2017 08:15 am ET
Aethlon Medical Announces The Conclusion Of Hemopurifier Clinical Study
SAN DIEGO, March 13, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that the company has concluded an FDA-approved feasibility study designed to assess the safety of the Aethlon Hemopurifier® in health-compromised individuals. The single-site study was conducted at DaVita Med Center Dialysis in Houston, Texas.
Mar 08, 2017 09:25 am ET
Aethlon Medical To Present At ROTH Capital Partners 29th Annual Growth Stock Conference On March 14, 2017
SAN DIEGO, March 8, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that Jim Joyce, Chairman and CEO, will be presenting at the ROTH Capital Partners 29th Annual Growth Stock Conference in Dana Point, CA at 10:30 a.m. PT (1:30 p.m. ET) on Tuesday, March 14, 2017.
Mar 01, 2017 09:25 am ET
Aethlon Medical Announces the Grant of a European Patent Protecting Methods of Quantifying Exosomes
SAN DIEGO, March 1, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), announced today that the European Patent Office has granted European Patent Number 2591359, entitled "METHODS AND COMPOSITIONS FOR QUANTIFYING EXOSOMES."
Feb 24, 2017 09:25 am ET
Aethlon Medical CEO Note: Bill Gates on the Threat of Bioterrorism
SAN DIEGO, Feb. 24, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.
Feb 22, 2017 09:25 am ET
Aethlon Medical Reports Results of Cytomegalovirus, Epstein-Barr and Herpes Simplex Virus Studies
SAN DIEGO, Feb. 22, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today reported the results of a study that validated the ability of the Aethlon Hemopurifier® to capture latent viral pathogens that are associated with increased mortality in immune-suppressed sepsis patients and also contribute to organ rejection in transplant patients.
Feb 10, 2017 04:15 pm ET
Aethlon Medical Announces Fiscal 2017 Third Quarter Results
SAN DIEGO, Feb. 10, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a developer of immunotherapeutic technologies to combat infectious disease and cancer, today announced results for its fiscal third quarter year ended December 31, 2016.
Feb 06, 2017 09:25 am ET
Aethlon Medical To Host Third Quarter Fiscal 2017 Investor Call On February 10, 2017
SAN DIEGO, Feb. 6, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that it will host its Third Quarter Fiscal 2017 investor conference call and webcast on Friday, February 10, 2017 at 4:30 p.m. Eastern Time.
Jan 25, 2017 07:00 am ET
Researchers Announce Plans for Study of Candidate Blood Test to Detect Chronic Traumatic Encephalopathy (CTE) in Former NFL Players
HOUSTON and SAN DIEGO, Jan. 25, 2017 /PRNewswire/ -- Researchers with Exosome Sciences, Inc., a diagnostic subsidiary of Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company, today announced plans to initiate a clinical study involving retired NFL players and a data-supported biomarker candidate to detect and monitor Chronic Traumatic Encephalopathy (CTE) in living individuals. CTE is a neurodegenerative disease that has often been found in American football players, boxers and other individuals with a history of repetitive head trauma. At present, CTE diagnosis is determi
Jan 11, 2017 09:12 am ET
CEO Note - Clinical Study Update and a Review of 2016 Accomplishments
SAN DIEGO, Jan. 11, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.
Dec 21, 2016 09:25 am ET
Passage of the 21st Century Cures Act and its Potential Implications on Biodefense
SAN DIEGO, Dec. 21, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.
Dec 15, 2016 09:25 am ET
Aethlon Announces Initiation of Sepsis-Related Virus Study
SAN DIEGO, Dec. 15, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), announced today that it has initiated a research study to validate the ability of the Aethlon Hemopurifier® to capture viruses that are associated with increased mortality in immune-suppressed sepsis patients. The study is designed to validate the in vitro capture of Cytomegalovirus (CMV), Epstein-Barr virus (EBV) and Herpes Simplex Viruses (HSV). Upon successful completion, Aethlon will seek to demonstrate that the Hemopurifier can simultaneously capture all three viruses.
Nov 10, 2016 04:15 pm ET
Aethlon Medical Announces Fiscal 2017 Second Quarter Results
SAN DIEGO, Nov. 10, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a developer of immunotherapeutic technologies to combat infectious disease and cancer, today announced results for its fiscal second quarter year ended September 30, 2016.
Nov 03, 2016 10:25 am ET
Aethlon Medical To Host Second Quarter Fiscal 2017 Investor Call On November 10, 2016
SAN DIEGO, Nov. 3, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that it will host its Second Quarter Fiscal 2017 investor conference call and webcast on Thursday, November 10, 2016 at 4:30 p.m. Eastern Time.
Oct 13, 2016 10:11 am ET
Aethlon Medical Achieves DARPA Milestones, Including Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Validation
SAN DIEGO, Oct. 13, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), announced today that it has completed multiple milestone achievements under a contract with the Defense Advanced Research Projects Agency (DARPA), including a milestone validation that the Aethlon Hemopurifier® is able to capture the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The Hemopurifier® is a first-in-class medical device designed to rapidly eliminate viral pathogens from the circulatory system of infected individuals. The MERS-CoV milestone was predicated on demonstrating the capture of the
Oct 12, 2016 10:25 am ET
Aethlon Medical Announces Corporate Update Presentation At Next Week's 2016 Bio Investor Forum
SAN DIEGO, Oct. 12, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), announced today that Jim Joyce, Chairman and CEO, will be presenting a corporate update at the 2016 Bio Investor Forum in San Francisco, CA at 6:30 p.m. ET (3:30 a.m. PT) on Tuesday, October 18, 2016.
Sep 20, 2016 10:25 am ET
Aethlon Medical Updates Corporate Presentation Schedule
SAN DIEGO, Sept. 20, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today announced changes to its corporate presentation schedule over the coming month. On September 6th, the Company disclosed that its Chairman and CEO, Jim Joyce, would be presenting at the Aegis Capital 2016 Annual Growth Conference on Wednesday, September 21st.
Sep 12, 2016 10:25 am ET
Aethlon Medical To Present At The Rodman & Renshaw 18th Annual Global Investment Conference On September 13, 2016
SAN DIEGO, Sept. 12, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), announced today that Jim Joyce, Chairman and CEO, and Jim Frakes, Chief Financial Officer, will be presenting at the Rodman & Renshaw 18th Annual Global Investment Conference in New York, NY at 2:10 p.m. ET (11:10 a.m. PT) on Tuesday, September 13, 2016.
Sep 09, 2016 10:09 am ET
The Dilemma in Funding Zika and Other Pandemic Therapies
SAN DIEGO, Sept. 9, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.
Sep 06, 2016 10:25 am ET
Aethlon Medical Announces Upcoming September Investor And Industry Conferences
SAN DIEGO, Sept. 6, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), announced today its upcoming conference schedule for the month of September. Aethlon management will be presenting at the following conferences and is available for one-on-one meetings at the events. Additional details, including presentation and webcast information will be announced in the future, and will be posted on the investor relations section of the Aethlon website at www.aethlonmedical.com.
Aug 11, 2016 05:15 pm ET
Aethlon Medical Announces Fiscal 2017 First Quarter Results
SAN DIEGO, Aug. 11, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a developer of immunotherapeutic technologies to combat infectious disease and cancer, today announced results for its fiscal first quarter year ended June 30, 2016.
Aug 11, 2016 10:12 am ET
Aethlon Medical Announces Zika Virus Data
SAN DIEGO, Aug. 11, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a developer of immunotherapeutic technologies to combat infectious disease and cancer, announced today that its researchers have completed in vitro studies that demonstrate the rapid capture of Zika virus by the Aethlon Hemopurifier®. The Hemopurifier® is a leading broad-spectrum treatment countermeasure against viral pathogens that are untreatable with or resistant to antiviral drug therapies. At present, the immunotherapeutic technology is being advanced through an FDA approved human feasibility study. The
Aug 09, 2016 01:07 pm ET
Aethlon Medical To Host First Quarter Fiscal 2017 Investor Call On August 11, 2016
SAN DIEGO, Aug. 9, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that it will host its First Quarter Fiscal 2017 investor conference call and webcast on Thursday, August 11, 2016 at 4:30 p.m. Eastern Time.
Jun 29, 2016 05:15 pm ET
Aethlon Medical Announces Fiscal 2016 Results
SAN DIEGO, June 29, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a leading developer of immunotherapeutic technologies to combat infectious disease and cancer, today announced results for its fiscal year ended March 31, 2016.
Jun 28, 2016 10:15 am ET
Aethlon Medical Announces $12.5 Million At The Market Program
SAN DIEGO, June 28, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (the "Company") (Nasdaq: AEMD), a leading developer of immunotherapeutic technologies to combat infectious disease and cancer, announced today that it has filed a prospectus supplement under which it may sell up to $12,500,000 of its common stock through an "at-the-market" equity offering program.
Jun 27, 2016 10:45 am ET
Aethlon Medical Joins Russell Microcap® Index
SAN DIEGO, June 27, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), announced today that it has been added to the Russell Microcap® Index. The annual reconstitution of Russell U.S. Indexes became effective with the opening of the U.S. markets for trading today.
Jun 27, 2016 10:15 am ET
Aethlon Medical to Host Fourth Quarter and Full Year Fiscal 2016 Investor Call On June 29, 2016
SAN DIEGO, June 27, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that it will host its Fourth Quarter and Full Year Fiscal 2016 investor conference call and webcast on Wednesday, June 29, 2016 at 4:30 p.m. Eastern Time.
Jun 22, 2016 10:15 am ET
Aethlon Medical Set To Join Russell Microcap® Index
SAN DIEGO, June 22, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), announced today that it has been added to the preliminary list of new additions to join the Russell Microcap Index at the conclusion of the Russell U.S. Indexes annual reconstitution, effective after the U.S. market opens on June 27.
Jun 14, 2016 11:28 am ET
Aethlon Medical Announces Issuance Of Exosome Capture Patent
SAN DIEGO, June 14, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), announced today that U.S. Patent Number 9,364,601 (the "601 Patent"), related to methods for capturing an exosome from a patient, has been issued to the Company by the United States Patent and Trademark Office. The 601 Patent is an important addition to Aethlon's patent portfolio as it protects lectin-based exosome harvesting, diagnostics and therapeutic applications. In recent years, exosomes have emerged to become significant biomarker and therapeutic targets underlying a wide range of disease conditions, inclu
Jun 06, 2016 10:30 am ET
Aethlon Medical To Present Cancer And Infectious Disease Initiatives, As Well As Chronic Traumatic Encephalopathy (CTE) Candidate Biomarker Discovery At Tomorrow's BIO International Convention
SAN DIEGO, June 6, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), announced today that Jim Joyce, Chairman and CEO, will be presenting tomorrow (June 7th) at the BIO International Convention being held at Moscone Center in San Francisco, California. The presentation, which is scheduled to begin at 10:45AM (PT), will review Aethlon Medical's initiatives to combat cancer and infectious disease. Mr. Joyce will also present the discovery of a non-invasive candidate biomarker to diagnose CTE that was made in collaboration with Exosome Sciences, a majority-owned subsidiary of Aethlon
Jun 01, 2016 10:30 am ET
Aethlon Medical To Present At 2nd Annual Sachs Associates Immuno-oncology: BD&L And Investment Forum On June 3, 2016
SAN DIEGO, June 1, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that Jim Joyce, Chairman and CEO, will be presenting at the 2nd Annual Sachs Associates Immuno-oncology: BD&L and Investment Forum (http://www.sachsforum.com/2nd-immuno-oncology-bdl-and-investment-forum.html) at the Hyatt Chicago Magnificent Mile Hotel in Chicago, IL at 10:20 p.m. Central Time on Friday, June 3, 2016.
May 05, 2016 09:00 am ET
Aethlon Medical's CEO and Executive Chairman James Joyce Interviewed by The Life Sciences Report
Exosome Sciences, a majority-owned subsidiary of Aethlon Medical Inc. (NASDAQ: AEMD), is developing an exosome-based platform to diagnose a broad-spectrum of disease conditions. In this interview with The Life Sciences Report, Executive Chairman...
May 04, 2016 10:30 am ET
Aethlon Medical's Exosome Sciences Announces Production of ELLSA Exosome Isolation Platform
SAN DIEGO, May 4, 2016 /PRNewswire/ -- Exosome Sciences, Inc., in collaboration with majority shareholder Aethlon Medical, Inc., (Nasdaq: AEMD) announced today that it will initiate production of its ELLSA™ (Enzyme Linked Lectin Specific Assay) diagnostic platform to isolate disease-specific exosomes from bodily fluids. Exosome Sciences, Inc. (ESI) will make the platform available to collaborative institutes that are conducting research on exosomal biomarkers with the eventual goal of supporting a new generation of diagnostic products.
May 02, 2016 09:45 am ET
Aethlon Medical (AEMD) CEO Note: Hemopurifier Clinical Progression, USA Today on the Next Zika, Combating Bioterror & Pandemic Threats
SAN DIEGO, May 2, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.
Mar 31, 2016 10:30 am ET
Aethlon Medical Discloses Hemopurifier® Clinical Trial and Manufacturing Advancements
SAN DIEGO, March 31, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), reported that the recently appointed principal investigator of its FDA approved clinical study in Houston, Texas, has completed a six-treatment protocol of Hemopurifier therapy in an enrolled patient and has consented the enrollment of the next patient. The information was disclosed during an Annual Meeting of Stockholders conducted on March 29, 2016 in San Diego, California. Aethlon had previously disclosed in February 2016, that it had completed the formal training of its new principal investigator, Dr. Ronald
Mar 30, 2016 10:30 am ET
Aethlon Medical, Inc. Reports Annual Meeting Results
SAN DIEGO, March 30, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today reported the results of its Annual Meeting of Stockholders completed on March 29, 2016 in San Diego, California.
Mar 09, 2016 06:30 am ET
Aethlon Medical To Present At Roth Capital Partners 28th Annual Growth Stock Conference On March 16, 2016
SAN DIEGO, March 9, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that Jim Joyce, Chairman and CEO, will be presenting at the ROTH Capital Partners 28th Annual Growth Stock Conference in Laguna Niguel, CA at 10:30 a.m. PT (1:30 p.m. ET) on Wednesday, March 16, 2016.
Feb 25, 2016 08:30 am ET
Aethlon Medical's Exosome Sciences Announces the Publication of Preliminary Findings of a Blood Test to Detect Chronic Traumatic Encephalopathy (CTE) During Life
SAN DIEGO, Feb. 25, 2016 /PRNewswire/ -- Exosome Sciences, Inc., in collaboration with majority shareholder Aethlon Medical, Inc. (Nasdaq:AEMD) and investigators at Boston University and the University of Washington, announced today the published preliminary results of possibly the first blood test to detect the neurodegenerative disease, Chronic Traumatic Encephalopathy (CTE) during life. An early online version of these findings has been published in the Journal of Alzheimer's Disease. CTE is associated with exposure to repetitive head impacts, such as those experienced by American footbal
Feb 18, 2016 09:30 am ET
Aethlon Medical To Present At 4th Annual Sachs Cancer Bio Partnering & Investment Forum On February 24, 2016
SAN DIEGO, Feb. 18, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that Jim Joyce, Chairman and CEO, will be presenting at the 4th Annual Sachs Cancer Bio Partnering & Investment Forum at the New York Academy of Sciences in New York, NY at 2:20 p.m. ET on Wednesday, February 24, 2016.
Feb 05, 2016 09:32 am ET
Aethlon Medical to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference on February 10, 2016
SAN DIEGO, Feb. 5, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that Jim Joyce, Chairman and CEO, will be presenting at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference in New York, NY at 2:15 p.m. ET on Wednesday, February 10, 2016. Mr. Joyce will also participate in an Immunotherapy Panel discussion taking place at 3:15 p.m. ET.
Feb 04, 2016 04:10 pm ET
Aethlon Medical Announces Fiscal 2016 Third Quarter Results
SAN DIEGO, Feb. 4, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, today announced results for the third quarter of fiscal 2016 ended December 31, 2015.
Feb 03, 2016 09:30 am ET
Aethlon Medical Announces Dengue Virus Study Approval, Chikungunya Virus Capture Data and Completion of U.S. Principal Investigator Training
SAN DIEGO, Feb. 3, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that a human treatment study entitled: "A Clinical Safety Study of the Aethlon Hemopurifier® in Patients with Dengue Virus Infection," has been approved by the Institutional Ethics Committee (IEC) at the MAX Super Specialty Hospital in Delhi, India. The Aethlon Hemopurifier is a leading broad-spectrum treatment countermeasure against viral pathogens that are untreatable with or resistant to antiviral drug therapies.
Feb 01, 2016 09:30 am ET
Aethlon Medical to Present at the 18th Annual BIO CEO & Investor Conference
SAN DIEGO, Feb. 1, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that Jim Joyce, Chairman and CEO, will be presenting at the BIO CEO & Investor Conference in New York, NY at 3:30 p.m. ET on Tuesday, February 9, 2016.
Jan 29, 2016 09:30 am ET
Aethlon Medical To Host Third Quarter Fiscal 2016 Investor Call on February 4, 2016
SAN DIEGO, Jan. 29, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, today announced that it will host its Third Quarter Fiscal 2016 investor conference call and webcast on Thursday, February 4, 2016 at 4:30 p.m. Eastern Time.
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.